ACADIA PHARMACEUTICALS INC. Increase (Decrease) in Accounts Receivable
ACADIA PHARMACEUTICALS INC. (ACAD) reported Increase (Decrease) in Accounts Receivable of $29.19 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-05
- ACADIA PHARMACEUTICALS INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $15.29M, a 768.05% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $13.89M, a 98.36% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $5.61M, a 957.92% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $8.35M.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in accounts receivable for fiscal 2025 was $22.72M, a 4713.14% increase from fiscal 2024.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in accounts receivable for fiscal 2024 was $472.00K, a 98.69% decline from fiscal 2023.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in accounts receivable for fiscal 2023 was $36.07M.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in accounts receivable for fiscal 2022 was -$2.17M, a 113.47% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $29.19M 10-Q · filed 2026-08-05 | $34.80M derived: sum of 3 quarters · filed 2026-08-05 | $43.14M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $13.89M 10-Q · filed 2026-05-07 | $19.50M derived: sum of 2 quarters · filed 2026-05-07 | $27.84M derived: sum of 3 quarters · filed 2026-05-07 | $29.61M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $5.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $13.95M derived: sum of 2 quarters · filed 2026-02-26 | $15.71M derived: sum of 3 quarters · filed 2026-08-05 | $22.72M 10-K · filed 2026-02-26 |
| 2025-09-30 | $8.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $10.11M derived: sum of 2 quarters · filed 2026-08-05 | $17.11M 10-Q · filed 2025-11-06 | $17.64M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $8.77M 10-Q · filed 2026-08-05 | $9.30M derived: sum of 3 quarters · filed 2026-08-05 | $3.81M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $7.00M 10-Q · filed 2026-05-07 | $7.53M derived: sum of 2 quarters · filed 2026-05-07 | $2.04M derived: sum of 3 quarters · filed 2026-05-07 | $11.04M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $530.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$4.96M derived: sum of 2 quarters · filed 2026-02-26 | $4.04M derived: sum of 3 quarters · filed 2026-02-26 | $472.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | -$5.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.51M derived: sum of 2 quarters · filed 2025-11-06 | -$58.00K 10-Q · filed 2025-11-06 | $5.41M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $9.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $5.43M 10-Q · filed 2025-08-07 | $10.90M derived: sum of 3 quarters · filed 2026-02-26 | $21.85M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$3.57M 10-Q · filed 2025-05-08 | $1.90M derived: sum of 2 quarters · filed 2026-02-26 | $12.85M derived: sum of 3 quarters · filed 2026-02-26 | $28.79M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $5.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $16.41M derived: sum of 2 quarters · filed 2026-02-26 | $32.35M derived: sum of 3 quarters · filed 2026-02-26 | $36.07M 10-K · filed 2026-02-26 |
| 2023-09-30 | $10.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $26.89M derived: sum of 2 quarters · filed 2024-11-07 | $30.61M 10-Q · filed 2024-11-07 | $37.07M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $15.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $19.66M 10-Q · filed 2024-08-07 | $26.12M derived: sum of 3 quarters · filed 2025-02-27 | $13.90M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $3.72M 10-Q · filed 2024-05-09 | $10.18M derived: sum of 2 quarters · filed 2025-02-27 | -$2.04M derived: sum of 3 quarters · filed 2025-02-27 | $3.20M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $6.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$5.76M derived: sum of 2 quarters · filed 2025-02-27 | -$518.00K derived: sum of 3 quarters · filed 2025-02-27 | -$2.17M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$12.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$6.98M derived: sum of 2 quarters · filed 2023-11-03 | -$8.63M 10-Q · filed 2023-11-03 | -$4.96M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $5.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $3.59M 10-Q · filed 2023-08-03 | $7.26M derived: sum of 3 quarters · filed 2024-02-28 | $16.59M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$1.65M 10-Q · filed 2023-05-08 | $2.02M derived: sum of 2 quarters · filed 2024-02-28 | $11.35M derived: sum of 3 quarters · filed 2024-02-28 | $5.88M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $3.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $13.00M derived: sum of 2 quarters · filed 2024-02-28 | $7.53M derived: sum of 3 quarters · filed 2024-02-28 | $16.12M 10-K · filed 2024-02-28 |
| 2021-09-30 | $9.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $3.86M derived: sum of 2 quarters · filed 2022-11-03 | $12.45M 10-Q · filed 2022-11-03 | $14.35M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$5.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $3.12M 10-Q · filed 2022-08-09 | $5.02M derived: sum of 3 quarters · filed 2023-02-28 | $7.58M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $8.59M 10-Q · filed 2022-05-05 | $10.49M derived: sum of 2 quarters · filed 2023-02-28 | $13.05M derived: sum of 3 quarters · filed 2023-02-28 | $15.20M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $4.46M derived: sum of 2 quarters · filed 2023-02-28 | $6.61M derived: sum of 3 quarters · filed 2023-02-28 | $12.47M 10-K · filed 2023-02-28 |
| 2020-09-30 | $2.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $4.71M derived: sum of 2 quarters · filed 2021-11-09 | $10.56M 10-Q · filed 2021-11-09 | $15.54M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $2.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $8.00M 10-Q · filed 2021-08-05 | $12.98M derived: sum of 3 quarters · filed 2022-03-01 | $12.00M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $5.86M 10-Q · filed 2021-05-06 | $10.83M derived: sum of 2 quarters · filed 2022-03-01 | $9.86M derived: sum of 3 quarters · filed 2022-03-01 | $11.68M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $4.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $4.00M derived: sum of 2 quarters · filed 2022-03-01 | $5.82M derived: sum of 3 quarters · filed 2022-03-01 | $9.69M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$977.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $846.00K derived: sum of 2 quarters · filed 2020-11-04 | $4.71M 10-Q · filed 2020-11-04 | $10.85M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $1.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $5.69M 10-Q · filed 2020-08-06 | $11.82M derived: sum of 3 quarters · filed 2021-02-25 | $6.08M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $3.87M 10-Q · filed 2020-05-08 | $10.00M derived: sum of 2 quarters · filed 2021-02-25 | $4.26M derived: sum of 3 quarters · filed 2021-02-25 | $7.51M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $6.13M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $394.00K derived: sum of 2 quarters · filed 2021-02-25 | $3.65M derived: sum of 3 quarters · filed 2021-02-25 | $8.75M 10-K · filed 2021-02-25 |
| 2018-09-30 | -$5.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | -$2.49M derived: sum of 2 quarters · filed 2019-10-31 | $2.62M 10-Q · filed 2019-10-31 | $5.74M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $3.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $8.35M 10-Q · filed 2019-08-01 | $11.47M derived: sum of 3 quarters · filed 2020-02-27 | $14.10M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $5.10M 10-Q · filed 2019-05-02 | $8.22M derived: sum of 2 quarters · filed 2020-02-27 | $10.85M derived: sum of 3 quarters · filed 2020-02-27 | $14.79M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $5.75M derived: sum of 2 quarters · filed 2020-02-27 | $9.68M derived: sum of 3 quarters · filed 2020-02-27 | $11.44M 10-K · filed 2020-02-27 |
| 2017-09-30 | $2.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $6.56M derived: sum of 2 quarters · filed 2018-11-06 | $8.32M 10-Q · filed 2018-11-06 | $10.38M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $3.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $5.69M 10-Q · filed 2018-08-08 | $7.75M derived: sum of 3 quarters · filed 2019-02-27 | $11.30M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $1.76M 10-Q · filed 2018-05-04 | $3.82M derived: sum of 2 quarters · filed 2019-02-27 | $7.37M derived: sum of 3 quarters · filed 2019-02-27 | |
| 2016-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $5.61M derived: sum of 2 quarters · filed 2019-02-27 | $5.90M 10-K · filed 2019-02-27 | |
| 2016-09-30 | $3.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $3.84M 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | $293.00K 10-Q · filed 2017-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |